A new clinical trial involving tirzepatide was registered on September 18, 2026. The study, titled "Efficacy of Tirzepatide for Weight Management in Patients With Suboptimal Weight Loss After Bariatric Surgery: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial," is listed under identifier NCT07829198.
The trial is designed as a Phase 3, randomized, double-blind, placebo-controlled study. Its current status is not yet recruiting, meaning participant enrollment has not yet begun as of the listed date.
The study aims to evaluate tirzepatide specifically in patients who experienced suboptimal weight loss following bariatric surgery. As a placebo-controlled design, the trial will compare outcomes between participants receiving tirzepatide and those receiving a placebo. No results, efficacy data, or safety findings have been posted for this trial at this time.
Tirzepatide is currently an approved compound. This registration reflects an expansion of clinical investigation into its use for a specific patient population rather than a change in its existing approval status. Further updates will depend on when recruitment begins and when data becomes available.
Readers interested in background information can consult the compound overview for additional context on tirzepatide.